Esperion Non Current Assets Total from 2010 to 2024
| ESPR Stock | USD 1.91 0.04 2.05% |
Non Current Assets Total | First Reported 2000-03-31 | Previous Quarter 3.1 M | Current Value 4.7 M | Quarterly Volatility 28.3 M |
Check Esperion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Esperion main balance sheet or income statement drivers, such as Depreciation And Amortization of 155.8 K, Interest Expense of 61.9 M or Gross Profit of 69.3 M, as well as many exotic indicators such as Price To Sales Ratio of 2.52, Dividend Yield of 0.34 or Days Sales Outstanding of 88.37. Esperion financial statements analysis is a perfect complement when working with Esperion Therapeutics Valuation or Volatility modules.
Esperion | Non Current Assets Total |
Latest Esperion Therapeutics' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Esperion Therapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Esperion Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Esperion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Esperion Non Current Assets Total Regression Statistics
| Arithmetic Mean | 21,162,355 | |
| Geometric Mean | 5,829,814 | |
| Coefficient Of Variation | 131.64 | |
| Mean Deviation | 22,681,096 | |
| Median | 4,730,999 | |
| Standard Deviation | 27,858,346 | |
| Sample Variance | 776.1T | |
| Range | 81M | |
| R-Value | (0.05) | |
| Mean Square Error | 833.8T | |
| R-Squared | 0 | |
| Significance | 0.86 | |
| Slope | (306,806) | |
| Total Sum of Squares | 10865.2T |
Esperion Non Current Assets Total History
About Esperion Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Esperion Therapeutics income statement, its balance sheet, and the statement of cash flows. Esperion Therapeutics investors use historical funamental indicators, such as Esperion Therapeutics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Esperion Therapeutics investors may use each financial statement separately, they are all related. The changes in Esperion Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Esperion Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Esperion Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Esperion Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 4.7 M | 4.5 M |
Pair Trading with Esperion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Esperion Stock
| 0.64 | MRK | Merck Company Earnings Call This Week | PairCorr |
Moving against Esperion Stock
| 0.45 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.
The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Esperion Therapeutics Correlation against competitors. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Esperion Stock analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share 1.128 | Quarterly Revenue Growth 0.714 | Return On Assets (0.43) | Return On Equity (2.61) |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.